张雅文, 郑正, 奉建芳, 涂亮星, 范武发. 口服肝靶向纳米递药系统的研究进展J. 药学学报, 2025, 60(6): 1661-1670. DOI: 10.16438/j.0513-4870.2024-1311
引用本文: 张雅文, 郑正, 奉建芳, 涂亮星, 范武发. 口服肝靶向纳米递药系统的研究进展J. 药学学报, 2025, 60(6): 1661-1670. DOI: 10.16438/j.0513-4870.2024-1311
ZHANG Ya-wen, ZHENG Zheng, FENG Jian-fang, TU Liang-xing, FAN Wu-fa. Research progress of oral liver targeting nano-drug delivery systemJ. Acta Pharmaceutica Sinica, 2025, 60(6): 1661-1670. DOI: 10.16438/j.0513-4870.2024-1311
Citation: ZHANG Ya-wen, ZHENG Zheng, FENG Jian-fang, TU Liang-xing, FAN Wu-fa. Research progress of oral liver targeting nano-drug delivery systemJ. Acta Pharmaceutica Sinica, 2025, 60(6): 1661-1670. DOI: 10.16438/j.0513-4870.2024-1311

口服肝靶向纳米递药系统的研究进展

Research progress of oral liver targeting nano-drug delivery system

  • 摘要: 口服肝靶向纳米递药系统具有给药依从性好、不良反应低和安全性高等优点, 是最有潜力的给药方式。然而, 胃肠道和肝脏的生物及生理学屏障严重阻碍药物载体的口服吸收及在肝脏病变部位的分布。本文首先总结了口服肝靶向纳米递药系统在给药过程中遇到的主要生物和生理学屏障; 同时, 概括了近年来用于口服肝靶向递送的药物载体; 另外, 介绍了口服肝靶向纳米递药系统治疗肝脏相关疾病的研究进展, 为口服肝靶向纳米递药系统治疗肝脏相关疾病的研究提供思路。

     

    Abstract: Oral liver-targeting nano-drug delivery system is the most potential drug delivery method which has the advantages of good drug compliance, low side effects, and high safety. However, the biological and physiological barriers in the gastrointestinal tract and liver severely hinder the oral absorption and accumulation of drug carriers in the liver lesions. This review first describes the main biological and physiological barriers encountered by the oral liver-targeted nano-drug delivery system during the drug delivery period. Meanwhile, this article summarizes oral liver-targeting drug carriers in recent years. In addition, the research progress of oral liver-targeted nano-drug delivery system in the treatment of liver-related diseases is introduced, which provides ideas for the development of oral liver-targeting nano-drug delivery system in the liver-related disease treatment.

     

/

返回文章
返回